The ongoing US blockade of Cuba is preventing US researchers
from studying a drug they say is highly promising and could reduce the
need for amputations caused by diabetic foot ulcers.
The
drug, human recombinant epidermal growth factor (hrEGF), sold as
Heberprot-P, was developed by Cuban researchers at the Center for
Genetic Engineering and Biotechnology in Havana. Cuban doctors say it
has dramatically improved granulation of intractable diabetic foot
ulcers.
PDF can be accessed on C2S Blog.
No comments:
Post a Comment